Discontinued — last reported Q4 '15

Other

Fair Value Liabilities Measured On Recurring Basis Obligations

Edwards Lifesciences Fair Value Liabilities Measured On Recurring Basis Obligations increased by 395.0% to $9.90M in Q1 2026 compared to the prior quarter.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2014
Last reportedQ4 2015
Metric ID: other_fair_value_liabilities_measured_on_recurring_basis_192cee

Historical Data

2 periods
 Q4 '25Q1 '26
Value$2.00M$9.90M
QoQ Change—+395.0%
Range$2.00M – $9.90M

Frequently Asked Questions

What is Edwards Lifesciences's fair value liabilities measured on recurring basis obligations?
Edwards Lifesciences (EW) reported fair value liabilities measured on recurring basis obligations of $9.90M in Q1 2026.